Chief Medical Officer
Steven Fischkoff is a Board Certified Medical Oncologist who has been in the Pharmaceutical Industry for 29 years. At Knoll Pharmaceutics and through the acquisition by Abbott, Dr. Fischkoff served as the clinical lead for the development of Humira, taking it from first-in-man through approval in the US and the EU. At Medarex, he was responsible for the completion of the Phase 2 effort for ipilimumab (Yervoy) and designed the pivotal Phase 3 trial leading to its approval. At Palatin Technologies, he was responsible for the Phase 2 effort of bremelanotide, subsequently approved as Vyleesi for the treatment of premenopausal sexual arousal disorder. He spent 8 years at cell therapy companies: Celgene Cellular Therapeutics (spun off as Celularity), Lion and WindMIL, pursuing a number of oncology and inflammatory indications.